

S/N 10/081,050

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David W. Osborne	Examiner:	Lakshmi Channavajjala
Serial No.:	10/081,050	Group Art Unit:	1615
Filed:	February 20, 2002	Docket:	1195.346US1
Title:	Topical Dapsone for the Treatment of Acne		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), please charge Deposit Account No. 19-0743 in the amount of \$180.00 as set forth in 37 C.F.R. §1.17(p) to cover the requisite fee. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

04/11/2005 BABRAHA1 00000060 190743 10081050

01 FC:1806 180.00 DA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No : 10/081,050

Filing Date: February 20, 2002

Title: Topical Dapsone for the Treatment of Acne

Page 2

Dkt: 1195.346US1

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

DAVID W. OSBORNE

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
612-373-6900

Date

4/6/05

By

Richard A Schwartz
Reg. No. 48,105

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 6 day of April, 2005.

Name

David M. Boole


Signature

David M. Boole

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/081,050
Filing Date	February 20, 2002
First Named Inventor	Osborne, David
Group Art Unit	1615
Examiner Name	Channavajjala, Lakshmi

Sheet 1 of 1

Attorney Docket No: 1195.346US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-4,829,058	05/09/1989	Seydel, Joachim K., et al.	06/15/1987
	US-4,912,112	03/27/1990	Seydel, Joachim , et al.	02/06/1987
	US-5,733,572	03/31/1998	Unger, Evan C., et al.	11/29/1994
	US-6,056,955	05/02/2000	Fischetti, V. , et al.	09/14/1999
	US-6,248,324	06/19/2001	Fischetti, Vincent , et al.	09/28/2000
	US-6,254,866	07/03/2001	Fischetti, Vincent , et al.	09/01/2000
	US-6,277,399	08/21/2001	Fischetti, Vincent , et al.	09/28/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
--------------------	---------------------	------------------	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COLEMAN, MICHAEL D., et al., "Preliminary evaluation of the toxicity and efficacy of novel 2,4-diamino-5-benzylpyrimidine-sulphone derivatives using rat and human tissues in vitro", <u>Environmental Toxicology and Pharmacology</u> , 2(4), (December 20, 1996),389-395	
		COLEMAN, MICHAEL D., et al., "Studies on the inhibitory effects of analogues of dapsone on neutrophil function in vitro", <u>J. Pharm. Pharmacol.</u> 49(1), (January 1997),53-57	
		COLEMAN, MICHAEL D., et al., "Studies on the toxicity of analogues of dapsone in-vitro using rat, human and heterologously expressed metabolizing systems", <u>J. Pharm. Pharmacol.</u> , 48(9), (September 1996),945-950	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached